Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,332.00
Bid: 11,500.00
Ask: 12,400.00
Change: 0.00 (0.00%)
Spread: 900.00 (7.826%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-WHO says vaccine makers working non-stop to plug supply gap, urges patience

Thu, 28th Jan 2021 10:23

(Adds quote from WHO Europe vaccination expert)

* WHO urges solidarity amid vaccine rollout 'teething
problems'

* EU, Britain clash over delays in promised vaccine supply

* WHO's Kluge hopes 'extra future production' eases delays

* Russian vaccine data bound for Geneva -WHO Europe boss

By Stephanie Nebehay and John Miller

GENEVA, Jan 28 (Reuters) - The World Health Organization's
Europe director Hans Kluge said on Thursday vaccine
manufacturers were working non-stop to plug shortfalls in
supplies to countries struggling to contain the COVID-19
pandemic and urged them not to jostle for deliveries.

"Solidarity does not necessarily mean that each country in
the world starts (vaccinating) at exactly the same moment ...
The good understanding is that no one is safe before everyone is
safe," Kluge told an online news briefing.

Asked about delays in expediting Pfizer and
AstraZeneca vaccines to patients across the 27-nation
European Union, Kluge and a WHO-Europe vaccination expert,
Siddhartha Datta, appealed to governments and manufacturers to
cooperate in addressing "teething problems" in the rollout.

"The reality is there is a shortage of vaccines...(But) we
don't doubt that manufacturers and producers are working 24-7 to
bridge the gaps and we're confident the delays we are seeing now
are going to be made up by extra production in the future,"
Kluge said.

The WHO reiterated that vaccines should be shared equitably,
between poor and rich nations, to help end the pandemic with
Datta stressing COVID-19 vaccines were "a global public good".

As Kluge and Datta spoke, Europe's fight to secure COVID-19
vaccine supplies escalated as Britain demanded that it receive
all the shots it paid for after the EU asked AstraZeneca to
divert supplies from the UK.

The EU, whose members are far behind Israel, the United
Kingdom and the United States in dispensing vaccines, is
scrambling to obtain shots just as the West's biggest drugmakers
slow deliveries to the bloc due to production problems.

"We need to be patient, it will take time to vaccinate,"
Kluge said, adding that a total of 35 countries in Europe had
launched vaccinations with 25 million does administered so far.

PANDEMIC PARADOX

"This paradox, where communities sense an end is in sight
with the vaccine but, at the same time, are called to adhere to
restrictive measures in the face of a new threat, is causing
tension, angst, fatigue, and confusion. This is completely
understandable in these circumstances."

Kluge said continued high rates of transmission and emerging
variants of the virus made it urgent to vaccinate priority
groups, but acknowledged the rate of vaccine production and
distribution was not yet up to expectations.

He reiterated the WHO's stance that "vaccination passports"
- proof that somebody has been inoculated - will be important to
monitor inoculation coverage and efficacy of shots, but should
not be used as a litmus test for allowing people to travel.

Asked about WHO's scrutiny of Russia's Sputnik V vaccine,
Kluge said he had spoken with Moscow's ambassador on Wednesday
and that he could confirm that data needed by WHO scientists to
review the shot was en route to Geneva where the WHO is based.

The Russian vaccine is being distributed in Europe including
EU member state Hungary as well as elsewhere in the world, even
though the European Medicines Agency is not currently reviewing
it for approval.
(Reporting by Stephanie Nebehay and John Miller
Editing by Mark Heinrich)

More News
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more
25 Apr 2024 07:43

LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 06:30

Sanofi Q1 profit slips on generic competition, forex effects

April 25 (Reuters) - Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.